[Staphylococcus aureus Bacteraemia - an Interdisciplinary Challenge].
Anasthesiol Intensivmed Notfallmed Schmerzther. 2019 Mar;54(3):206-216
Authors: Hagel S, Kaasch AJ, Weis S, Seifert H, Pletz MW, Rieg S
BACKGROUND: Staphylococcus aureus is the second-most-common pathogen among bloodstream infections. Due to a high hospital mortality rate (15 - 40%), frequent complications and recurrences the clinical management of Staphylococcus aureus bacteremia (SAB) is distinct from bacteremia from other pathogens.
METHODS: A literature search was performed using PubMed. Guidelines and best practice expert recommendations were included.
RESULTS: The detection of S. aureus in blood culture should always be considered clinically relevant. The drug of choice for treatment of a bloodstream infection with methicillin-sensitive S. aureus is flucloxacillin (8 - 12 g i. v./d). In a bloodstream infection with methicillin-resistant S. aureus (MRSA) vancomycin or daptomycin (the latter not in pneumonic focus) are recommended. Follow-up blood cultures, source identification, including transoesophageal echocardiography in patients with risk profile, and rapid source control are important measures. The duration of therapy is at least 14 days with uncomplicated SAB, whereby the entire therapy should be carried out intravenously. In case of complicated SAB, a total therapy duration of at least 4 - 6 weeks is recommended. Adherence to this set of measures can reduce mortality by up to 50%.
CONCLUSION: SAB is associated with high morbidity and mortality. Clinical management is complex. By adhering to diagnostic and therapeutic measures, the prognosis can be improved.
PMID: 30866024 [PubMed - in process]